UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recent advances in the treatment of acute lymphoblastic leukemia

Leukemia & lymphoma, 2019-09, Vol.60 (11), p.2606-2621

2019

Volltextzugriff (PDF)

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

Leukemia & lymphoma, 2014-07, Vol.55 (7), p.1451-1462

2014

Volltextzugriff (PDF)

Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US

Journal of medical economics, 2019-11, Vol.22 (11), p.1113-1118

2019

Volltextzugriff (PDF)

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Leukemia & lymphoma, 2019-06, Vol.60 (7), p.1767-1774

2019

Volltextzugriff (PDF)

Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors

Leukemia & lymphoma, 2022-03, Vol.63 (4), p.885-893

2022

Volltextzugriff (PDF)

Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States

Leukemia & lymphoma, 2019-02, Vol.60 (3), p.668-674

2019

Volltextzugriff (PDF)

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Leukemia & lymphoma, 2018-09, Vol.59 (9), p.2238-2241

2018

Volltextzugriff (PDF)

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis

Leukemia & lymphoma, 2021-01, Vol.62 (1), p.224-228

2021

Volltextzugriff (PDF)

Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?

Expert opinion on pharmacotherapy, 2015-05, Vol.16 (7), p.999-1007

2015

Volltextzugriff (PDF)

Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model

Journal of medical economics, 2018-10, Vol.21 (10), p.1036-1040

2018

Volltextzugriff (PDF)

Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase

Journal of medical economics, 2017-09, Vol.20 (9), p.1007-1012

2017

Volltextzugriff (PDF)

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response

Leukemia & lymphoma, 2016-04, Vol.57 (4), p.812-819

2016

Volltextzugriff (PDF)

Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response

Leukemia & lymphoma, 2012-08, Vol.53 (8), p.1452-1460

2012

Volltextzugriff (PDF)

Emerging drugs for acute lymphocytic leukemia

Expert opinion on emerging drugs, 2014-03, Vol.19 (1), p.37-50

2014

Volltextzugriff (PDF)

Blinatumomab for the treatment of acute lymphoblastic leukemia: an update

Expert opinion on orphan drugs, 2019-02, Vol.7 (2), p.41-46

2019

Volltextzugriff (PDF)

Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model

Journal of Medical Economics, 2018, Vol.21 (10), p.1036-1040

2018

Volltextzugriff (PDF)

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response

Leukemia & Lymphoma, 2016, Vol.57 (4), p.812-819

2016

Volltextzugriff (PDF)

Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens

Leukemia & lymphoma, 2024-06, p.1

2024

Volltextzugriff (PDF)

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

Leukemia & lymphoma, 2023-02, Vol.64 (3), p.746-749

2023

Volltextzugriff (PDF)

Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals

Leukemia & lymphoma, 2023-01, Vol.64 (1), p.79-86

2023

Volltextzugriff (PDF)

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Leukemia & lymphoma, 2022-11, Vol.63 (13), p.3105-3116

2022

Volltextzugriff (PDF)

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

Leukemia & lymphoma, 2020-11, Vol.61 (13), p.3120-3127

2020

Volltextzugriff (PDF)

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Leukemia & lymphoma, 2020-10, Vol.61 (12), p.2811-2820

2020

Volltextzugriff (PDF)

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Leukemia & lymphoma, 2020-07, Vol.61 (8), p.2012-2015

2020

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis E-Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(6)

Publikationsform

Artikel
(29)
Berichte
(3)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recent advances in the treatment of acute lymphoblastic leukemia

Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia

Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US

A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis

Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors

Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States

Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia

Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis

Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia?

Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model

Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response

Molecular monitoring 101: helping your patients with chronic myeloid leukemia to understand the meaning of molecular response

Emerging drugs for acute lymphocytic leukemia

Blinatumomab for the treatment of acute lymphoblastic leukemia: an update

Economic value of regular monitoring of response to treatment among US patients with chronic myeloid leukemia based on an economic model

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response

Advances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens

Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring

Incidence of adverse effects in patients receiving ponatinib with concomitant azole antifungals

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment

Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Aktive Filter

Suchergebnisse filtern